Read previous post:
Shares of the Theratechnologies fell in half last June when Ferrer announced it would withdraw the marketing authorization application with the European Medicines Agency for Egrifta, the company's tesamorelin application proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
Canaccord Genuity maintains buy on Theratechnologies following Q3 results

Theratechnologies (TSX:TH) third quarter results were a little softer than he expected, but Canaccord Genuity analyst Neil Maruoka is sticking...

Close